Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

reach out to our knowledgeable Lung Health Navigators to determine if you are eligible for screening and to help you through the process. Note: options to cover certain expenses may be available due ...

Australian cancer ... help. Patient groups and experts are calling on Health Minister Mark Butler to intervene and overrule ...

Exposure to poor air quality, using tobacco products, or not getting recommended vaccinations can all negatively impact your lung health. This may cause your COPD to progress more quickly to the next ...

Investing.com -- Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned ...

Brian Beers is a digital editor, writer, Emmy-nominated producer, and content expert with 15+ years of experience writing about corporate finance & accounting, fundamental analysis, and investing ...

Abravanel and his colleagues collected 67 tumour biopsies from 60 people with metastatic breast cancer, meaning it had spread to other organs, such as the liver, brain and lungs. They found that ...